Anthropic Says It Will Revolutionize Biology—Some Day

Two years ago, Anthropic CEO Sam Amodei expressed optimism about AI's potential to accelerate biological research by a thousand years within a five to ten-year period. Recently, the company announced its rapid expansion into biology and medicine, predicting that AI could potentially cure most human diseases in the same timeframe, and promised a surge of AI-accelerated drug discoveries.

This new IPO filing still emphasizes AI's capability to "profoundly accelerate the rate of progress in biology and medicine" and compress "decades of scientific progress into years." However, it remains cautious about turning potential into reality. To achieve this, Anthropic teams need firsthand experience in scientific research and drug discovery, which requires them to engage in activities outside their historical software and research experience, such as handling hazardous materials, operating laboratory equipment, and complying with regulations.

The company also downplayed its earlier claims about the enzyme discovery, stating it "might have the potential to be developed into a novel biotechnology tool, perhaps for gene editing." While the IPO filing highlights Anthropic's shift towards becoming a core part of the biotech industry, researchers remain skeptical about the real-world utility of the enzyme discovery.

Even with AI's help in sorting out viable drug candidates and targets, the lengthy, costly, and uncertain drug development process still lies ahead, requiring multiple rounds of testing in test tubes, animals, and eventually, humans.